Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


2 Am J Hematol
4 Ann Hematol
7 Blood
2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Res
1 Eur J Haematol
1 Eur J Immunol
1 Int J Hematol
1 J Biol Chem
1 J Clin Oncol
1 J Immunol
7 J Pediatr Hematol Oncol
5 Leuk Lymphoma
6 Leukemia
1 Oncogene
4 Oncol Rep
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. LEUNG GMK, Zhang C, Ng NKL, Yang N, et al
    Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
    Am J Hematol. 2019 Mar 22. doi: 10.1002/ajh.25469.
    PubMed     Text format     Abstract available

  2. BHATT VR, Shostrom V, Armitage JO, Gundabolu K, et al
    Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.
    Am J Hematol. 2019 Mar 18. doi: 10.1002/ajh.25464.
    PubMed     Text format    

    Ann Hematol

  3. CASTELLI R, Rossi V, Della Porta MG, Schiavon R, et al
    Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.
    Ann Hematol. 2018;97:2523-2525.
    PubMed     Text format    

  4. JIN Z, Xiang R, Qing K, Li X, et al
    The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Ann Hematol. 2018;97:1327-1335.
    PubMed     Text format     Abstract available

  5. BRUNELLO L, Passera R, Dellacasa CM, Giaccone L, et al
    Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients.
    Ann Hematol. 2018;97:2205-2215.
    PubMed     Text format     Abstract available

  6. KONISHI T, Doki N, Kishida Y, Nagata A, et al
    Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission.
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03668.
    PubMed     Text format    


  7. WOOD B, Wu D, Crossley B, Dai Y, et al
    Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    Blood. 2018;131:1350-1359.
    PubMed     Text format     Abstract available

  8. DIMIER N, Delmar P, Ward C, Morariu-Zamfir R, et al
    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
    Blood. 2018;131:955-962.
    PubMed     Text format     Abstract available

  9. SCHUURHUIS GJ, Heuser M, Freeman S, Bene MC, et al
    Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
    Blood. 2018;131:1275-1291.
    PubMed     Text format     Abstract available

  10. SOIFFER RJ, Davids MS, Chen YB
    Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.
    Blood. 2018;131:1073-1080.
    PubMed     Text format     Abstract available

  11. COOLEY S, Parham P, Miller JS
    Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
    Blood. 2018 Jan 22. pii: blood-2017-08-752170. doi: 10.1182/blood-2017-08-752170
    PubMed     Text format     Abstract available

  12. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Text format     Abstract available

  13. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Text format     Abstract available

    BMC Cancer

  14. JIN M, Hu Y, Wu W, Luo Y, et al
    Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
    BMC Cancer. 2019;19:242.
    PubMed     Text format     Abstract available

  15. CERVEIRA N, Ferreira RB, Bizarro S, Correia C, et al
    Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.
    BMC Cancer. 2018;18:1229.
    PubMed     Text format     Abstract available

    Cancer Chemother Pharmacol

  16. RIVERA-DEL VALLE N, Cheng T, Irwin ME, Donnella H, et al
    Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Cancer Chemother Pharmacol. 2018;81:483-495.
    PubMed     Text format     Abstract available

    Cancer Res

  17. ZHOU M, Zhou K, Cheng L, Chen X, et al
    MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL.
    Cancer Res. 2018;78:1632-1642.
    PubMed     Text format     Abstract available

    Eur J Haematol

  18. NORGAARD JM, Friis LS, Kristensen JS, Severinsen MT, et al
    Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia.
    Eur J Haematol. 2019 Mar 19. doi: 10.1111/ejh.13229.
    PubMed     Text format     Abstract available

    Eur J Immunol

  19. AMES PR, Merashli M, Gentile F
    Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
    Eur J Immunol. 2019 Mar 20. doi: 10.1002/eji.201848042.
    PubMed     Text format    

    Int J Hematol

  20. SASAKI H, Mitani S, Kusumoto S, Marumo Y, et al
    Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2019 Mar 16. pii: 10.1007/s12185-019-02628.
    PubMed     Text format     Abstract available

    J Biol Chem

  21. NIE M, Wang Y, Guo C, Li X, et al
    CARM1-mediated methylation of protein arginine methyltransferase 5 represses human gamma-globin gene expression in erythroleukemia cells.
    J Biol Chem. 2018;293:17454-17463.
    PubMed     Text format     Abstract available

    J Clin Oncol

  22. WEI AH, Strickland SA Jr, Hou JZ, Fiedler W, et al
    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    J Clin Oncol. 2019 Mar 20:JCO1801600. doi: 10.1200/JCO.18.01600.
    PubMed     Text format     Abstract available

    J Immunol

  23. PALAZZO A, Herter S, Grosmaire L, Jones R, et al
    The PI3Kdelta-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    J Immunol. 2018;200:2304-2312.
    PubMed     Text format     Abstract available

    J Pediatr Hematol Oncol

  24. HORI D, Kobayashi R, Suzuki D, Sano H, et al
    Successful Treatment of Mediastinal gammadelta T-Cell Lymphoblastic Lymphoma in a 3-Year-Old Girl by Allogeneic Cord Blood Transplantation.
    J Pediatr Hematol Oncol. 2018;40:e311-e314.
    PubMed     Text format     Abstract available

  25. ALPARSLAN C, Yavascan O, Kasap Demir B, Atmis B, et al
    Successful Management of a Rare Cause of Hemolytic Uremic Syndrome With Eculizumab in a Child.
    J Pediatr Hematol Oncol. 2018;40:401-404.
    PubMed     Text format     Abstract available

  26. QUE LP, Huang K, Fang JP, Xu HG, et al
    Reassessment of the Risk-stratified GD-2008 ALL Protocol.
    J Pediatr Hematol Oncol. 2018;40:472-477.
    PubMed     Text format     Abstract available

  27. OZDEMIR N, Koc B, Uysalol EP, Bayram C, et al
    A Rare Case of Pediatric Bone Precursor B-Cell Lymphoma Presenting With Multiple Fractures.
    J Pediatr Hematol Oncol. 2018;40:489-490.
    PubMed     Text format    

  28. MORETTO A, Zanella A, Ciceri V, Rota M, et al
    Induction Dosage of Propofol for Repeated Sedations in Children With Hematological Disorders.
    J Pediatr Hematol Oncol. 2018;40:e295-e298.
    PubMed     Text format     Abstract available

  29. NIKANJAM M, Sun A, Albers M, Mangalindin K, et al
    Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience.
    J Pediatr Hematol Oncol. 2018;40:e273-e277.
    PubMed     Text format     Abstract available

  30. SOWITHAYASAKUL P, Sinlapamongkolkul P, Treetipsatit J, Vathana N, et al
    Hematologic Malignancies Associated With Mediastinal Germ Cell Tumors: 10 Years' Experience at Thailand's National Pediatric Tertiary Referral Center.
    J Pediatr Hematol Oncol. 2018;40:450-455.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  31. OO ZM, Illendula A, Grembecka J, Schmidt C, et al
    A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFbeta in leukemic cells.
    Leuk Lymphoma. 2018;59:2188-2200.
    PubMed     Text format     Abstract available

  32. KOMMALAPATI A, Kushchayeva Y, Tella SH
    Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database.
    Leuk Lymphoma. 2018;59:2254-2257.
    PubMed     Text format    

  33. LAMBA JK, Voigt AP, Chauhan L, Shin M, et al
    CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
    Leuk Lymphoma. 2018;59:2250-2253.
    PubMed     Text format    

  34. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Text format     Abstract available

  35. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.
    PubMed     Text format    


  36. MARSILIO S, Khiabanian H, Fabbri G, Vergani S, et al
    Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
    Leukemia. 2018;32:1041-1044.
    PubMed     Text format    

  37. SANARICO AG, Ronchini C, Croce A, Memmi EM, et al
    The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
    Leukemia. 2018;32:911-919.
    PubMed     Text format     Abstract available

  38. MAURA F, Petljak M, Lionetti M, Cifola I, et al
    Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
    Leukemia. 2018;32:1044-1048.
    PubMed     Text format    

  39. PETER B, Bibi S, Eisenwort G, Wingelhofer B, et al
    Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Leukemia. 2018;32:1016-1022.
    PubMed     Text format     Abstract available

  40. LUCAS N, Duchmann M, Rameau P, Noel F, et al
    Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0447.
    PubMed     Text format     Abstract available

  41. VISHWAKARMA BA, Gudmundsson KO, Oakley K, Han Y, et al
    Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development.
    Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0445.
    PubMed     Text format    


  42. PATRUSSI L, Capitani N, Cattaneo F, Manganaro N, et al
    p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from beta-arrestin at early endosomes.
    Oncogene. 2018;37:1534-1550.
    PubMed     Text format     Abstract available

    Oncol Rep

  43. LEE HR, Baek KH
    Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
    Oncol Rep. 2019 Mar 13. doi: 10.3892/or.2019.7059.
    PubMed     Text format     Abstract available

  44. WANG H, Dong R, Fan WW, Zheng XC, et al
    Timosaponin AIII induces autophagy of Tcell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway.
    Oncol Rep. 2019 Mar 15. doi: 10.3892/or.2019.7072.
    PubMed     Text format     Abstract available

  45. HUANG R, Liao X, Li J, Wei J, et al
    Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Oncol Rep. 2019 Mar 18. doi: 10.3892/or.2019.7075.
    PubMed     Text format     Abstract available

  46. LI Y, Zhao L, Li N, Miao Y, et al
    [Corrigendum] miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
    Oncol Rep. 2019 Mar 13. doi: 10.3892/or.2019.7057.
    PubMed     Text format     Abstract available

    PLoS One

  47. PANDITA A, Ramadas P, Poudel A, Saad N, et al
    Differential expression of miRNAs in acute myeloid leukemia quantified by Nextgen sequencing of whole blood samples.
    PLoS One. 2019;14:e0213078.
    PubMed     Text format     Abstract available

  48. NG KP, Manjeri A, Lee LM, Chan ZE, et al
    The arginase inhibitor Nomega-hydroxy-nor-arginine (nor-NOHA) induces apoptosis in leukemic cells specifically under hypoxic conditions but CRISPR/Cas9 excludes arginase 2 (ARG2) as the functional target.
    PLoS One. 2018;13:e0205254.
    PubMed     Text format     Abstract available

  49. PILLING LC, Atkins JL, Kuchel GA, Ferrucci L, et al
    Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years.
    PLoS One. 2018;13:e0203504.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.